Korro Bio, Inc. - 8-K Filing

Korro Bio reports preclinical data for KRRO-111 showing >95% mRNA editing and plans regulatory submission in H1 2027 (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $KRRO

Read the full article at SEC EDGAR

More Regulatory news